6 results
Search Results
Now showing 1 - 6 of 6
Article Citation - WoS: 6Citation - Scopus: 6Covid-19 Infection in Peritoneal Dialysis Patients: \ra Comparative Outcome Study With Patients on \rhemodialysis and Patients Without Kidney Disease(Aves, 2022) Kazancıoğlu, Rümeyza; Ozturk, Savas; Turgutalp, Kenan; Gürsu, Meltem; Arıcı, Mustafa; Oruç, Ayşegül; Ateş, Kenan; Odabas, Ali Riza; Bek, Sibel GökçayObjectives: There is limited data about coronavirus disease-19 (COVID-19) characteristics and results in peritoneal dialysis \r(PD) patients. This study aimed to investigate the characteristics and outcomes among PD patients and compare them with \rmatched hemodialysis (HD) patients and a control group without kidney disease.\rMethods: We included 18 PD patients and consecutive age- and gender-matched 18 HD and 18 patients without kidney \rdisease (control group) registered into the Turkish Society of Nephrology database including 1301 COVID-19 patients. We \rcompared demographic, clinical, radiological, laboratory data, and outcomes namely intensive care unit (ICU) admission, \rmechanical ventilation, mortality, and composite outcome (death and/or ICU admission).\rResults: ICU admission, mechanical ventilation, and mortality rates in PD patients (27.8%, 22.2%, and 22.2%, respectively) \rand the HD group (16.7%, 11.1%, and 16.7%, respectively) were higher than the control group (11.1%, 11.1%, and 5.6%, \rrespectively), but intergroup comparison did not reveal difference. A total of 11 (20.3%) patients had composite outcome \r(6 PD patients, 3 HD patients, and 2 patients in the control group). In Cox regression analysis, higher age and higher CRP level were related to increased risk of composite outcome. Adjusted rate of composite outcome in PD group was significantly higher than \rthe control group (P = .050). This rate was similar in HD and control groups (P = .30).\rConclusions: Combined in-hospital mortality and/or ICU admission of PD patients with COVID-19 was significantly higher than the control \rpatients. There is a need for careful surveillance of PD patients for infection signs and prompt treatment of COVID-19.Article Citation - WoS: 2The Impact of Vaccination Among Hospitalized Patients With the Diagnosis of Covid-19(Doc design informatics Co Ltd, 2023) Yıldız, Yeşim; Özger, Hasan Selçuk; Acar, Ali; Keskin, Ayşegül Seremet; Binay, Umut Devrim; Ünlü, Gülten; Diseases, The Adult Immunization Study Group Of The Turkish Society Of Clinical Microbiology And Infectious; Seremet-Keskin, Aysegul; Azap, Alpay; Senol, Esin; Bayındır, Yasar; Kaya, Safak; Saygideger, Yasemin; Mete, Ayşe ÖzlemObjective: We aimed to investigate the vaccination status and the risk factors for the in- tensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpa- tients, divided into two groups as ‘fully’ and ‘partially’ vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mel- litus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the pre- dominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group’s need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vacci- nated were associated with the need for ICU support. Therefore, all countries should con- tinuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.Article Citation - Scopus: 1Determination of the Knowledge Levels of Nurses Regarding Central Venous Catheter Care(Galenos Publ House, 2022) Turkkan, Hicran; Ayyildiz, Tulay Kuzlu; Sonmez, MunevverIntroduction: It is important that pediatric nurses have sufficient knowledge in the prevention of central catheter-related blood circulation infections. This study was carried out to determine knowledge levels of the nurses, who were working in pediatric clinics, regarding central venous catheter care.Methods: The universe of the study was composed of 118 nurses, who were working in pediatric clinic of a public hospital (n=50) and a training hospital (n=68) between May-June 2019. No sample was selected; and 88 nurses, who were eligible for the sample and study criteria and approved to participate during the dates of data collection (May-June 2019) were included in the study. 75% of the universe was reached. Personal information form for the identification of demographic characteristics and working lives of the nurses and the form for the knowledge levels of the nurses regarding central venous catheter care were used to collect data.Results: At the end of statistical assessment, central venous catheter care mean score of nurses was found to be 8.35+2.36 (0-12). In addition, it was determined that no significant differences were found between central venous catheter scores of the nurses based on age, sex, marital status, working institution, working department, working year and their states of providing central venous catheter care (p>0.05). A significant difference was detected between nurses' states of having knowledge and education regarding central venous catheter and their central venous catheter scores (p<0.05). Conclusion: It was found that the knowledge points of the nurses for central venous catheter care were insufficient. It is recommended to increase in-service training in line with the protocol/procedure/ instructions regarding central venous catheter care.Article Citation - WoS: 4Citation - Scopus: 3Management of Chronic Hepatitis B in Special Patient Groups: a Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023(Doc design informatics Co Ltd, 2023) Tekin, Sueda; Karakecili, Faruk; Binay, Umut Devrim; Celik, Ilhami; Tulek, Necla; Tutuncue, Ediz; Demirturk, Nese; Tütüncü, Ediz; Yılmaz, EmelTurkish Society of Clinical Microbiology and Infectious Diseases Viral Hepatitis Working Group updated the consensus report on the management of chronic hepatitis B (CHB) in private hosts and special situations. Relevant literature and international guidelines are reviewed, and agreed recommendations are presented at the end of each chapter. In the report, treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection, management of HBV and hepatitis C virus (HCV) coinfection, management of CHB in severe COVID-19 patients, non-transplant immunocompromised patients.Article Evaluation of Covid-19 Cases Who Received Immunosuppressive Therapy at a Tertiary Care Hospital(Doc design informatics Co Ltd, 2022) Sayar, Merve Sefa; Acar, Ali; Bulut, Dilek; Celik, Sebahattin; Oguz, EminObjective: Immunosuppressive drugs are included in the treatment protocols of severe COVID-19 cases that may present with cytokine storm. In this study, we aimed to examine the characteristics of COVID-19 patients who received immunosuppressive therapy Methods: Patients diagnosed with COVID-19 and followed in the quarantine wards of our hospital between 01.03.2020-24.05.2020 were included in the study. Patient information was obtained retrospectively from patient files and discharge reports, and 263 COVID-19 patients-aged 18 and over-were included in the study. Results: The median age of the patients who received immunosuppressive therapy was 60.74 +/- 1.96, and 39.6% of them were women. The average symptom duration of the patients examined in the study at the time of admission to the hospital was 4.59 +/- 0.29 days. There was a significant difference in age, lymphocyte count, neutrophil/lymphocyte ratio, C-reactive protein, ferritin, D-Dimer, blood oxygen saturation, fever after antiviral therapy, qSOFA score, and total hospital stay between the two groups that received and did not receive immunosuppressive therapy (p<0.05). The need for immunosuppressive therapy increased 15.9 times over the age of 40, 15.6 times in the presence of diffuse involvement on thoracic CT, 6.6 times in the presence of chronic disease, 2.7 times in the presence of thrombocytopenia, and 1.7 times in the presence of lymphopenia (p <0.05).Conclusions: We observed that patients whose immunosuppressive therapy was added to their treatment protocols were admitted to the hospital later than others, had more prevalent involvement in thorax CT, high acute phase reactants, low SPO2, and more than one underlying disease.Article Tedavi Alan Kronik Hepatit B Hastalarında Serum Kantitatif Hbsag Düzeyi ile Viral Yük Arasındaki İlişkinin Araştırılması(Pamukkale University, 2020) Demirelli, Meryem; Tülek, Necla; Temoçin, Fatih; Yücel, Doğan; Erdinç, Fatma Şebnem; Ertem, Günay; Erdinc, SebnemAmaç: Yakın geçmişe kadar HBsAg sadece hepatit B enfeksiyonun tanısında kullanılırken, günümüzde serum HBsAg kantitasyonu (qHBsAg)’nun, hepatit B virüsü (HBV) enfeksiyonunun viral monitörizasyonunda kullanılabileceğine dair veriler artmaya başlamıştır. Bu çalışmada inaktif hepatit B taşıyıcıları ile kronik aktif hepatit B hastaları arasındaki qHBsAg ile HBV DNA düzeyleri karşılaştırılmış ve tedavi başlanmış hastalarda tedavi süresince qHBsAg ile HBVDNA seyri izlenerek aralarındaki ilişki değerlendirilmiştir. Gereç ve yöntem: Çalışma Ankara Eğitim ve Araştırma Hastanesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği’nde yapılmıştır. Kronik hepatit B (KHB) tanısıyla tedavi alan 71 hasta ve inaktif HBsAg taşıyıcısı 74 hasta çalışmaya dahil edildi. Bu hastalarda serum qHBsAg düzeyleri Elecsys HBsAg II cihazı ile çalışıldı. Bulgular: Nükleoz(t)id analoğu ile tedavi edilen hastalarda 6. ve 12. aydaki serum qHBsAg düzeyi ile HBVDNA arasında pozitif yönde bir korelasyon görüldü ve her iki parametrenin altı ay ve bir yıllık izlemindeki düşüş istatiksel olarak anlamlı bulundu (qHBsAg 6ay p=0,03, qHBsAg 12 ay p=0,001, HBV DNA 6 ay p=0,001, HBV DNA 12 ay p=0,001). Peg-IFN tedavisi alan kronik hepatit B hastalarında ise serum qHBsAg düzeyi ile HBVDNA arasında tedavi başlangıcı ve 6. ayında anlamlı bir ilişki olmayıp tedavi sonunda pozitif yönde korelasyon görüldü. PEG-IFN tedavisi alan hasta grubunda ise qHBsAg seviyeleri ile HBV DNA arasındaki korelasyon tedavi sonunda anlamlı (p=0,01) olarak saptandı.
